Altimmune
ALT
210 hedge funds and large institutions have $456M invested in Altimmune in 2026 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 86 increasing their positions, 33 reducing their positions, and 18 closing their positions.
589% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $2.09M
222% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 18
161% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 33
114% more capital invested
Capital invested by funds: $214M → $456M (+$243M)
23.84% more ownership
Funds ownership: 53.32% → 77.16% (+24%)
21% more funds holding
Funds holding: 173 → 210 (+37)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$57.5M |
| 2 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$29.9M |
| 3 |
BlackRock
New York
|
+$22.7M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$20M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$19.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$8.15M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$1.92M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.78M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.57M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.21M |
ALT Hedge Fund Activity: Q2 2026 in Review
210 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2026, worth a combined $456M — up 114% from $214M a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new ALT positions and 18 closed out — a net gain of 40 holders — while 86 added to existing stakes and 33 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $57.5M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $8.15M sold.
- 210 institutional investors held Altimmune (ALT) as of Q2 2026, up from 173 in Q1 2026.
- Funds reported $456M of Altimmune stock for Q2 2026, up 114% quarter-over-quarter.
- 58 funds opened new Altimmune positions in Q2 2026 and 18 closed out, a net change of +40 holders.
- The largest Altimmune buyer in Q2 2026 was Deep Track Capital, an estimated $57.5M added.
- The largest Altimmune seller in Q2 2026 was Alyeska Investment Group, an estimated $8.15M sold.
Based on aggregated 13F filings for Q2 2026.